RPRX
I think the market cap for RPRX is crazy, or else I wouldn't have repurchased my shares after paying the tax man. It is reasonable that RPRX should have a $250 M++ market cap right now based just on Proellex.
In my view--and, I believe, in Dewophile's view--RPRX is as low-risk as you can get for a biotech (which is to say, still pretty risky). I guess people would rather throw money at much longer shots, of which any of us could name dozens.
From a clinical viewpoint, I don't see many instances where the evidence for efficacy is as clear-cut as with Proellex, nor do I see many instances where the superiority over current therapies in terms of both safety and efficacy is so obvious. I also find Dewophile's confidence in the safety very reassuring, given that he works in reproductive medicine. I find it reassuring that I have yet to hear substantive criticism from anyone--either online or among my colleagues in medicine and industry--about Proellex. I'd also like to note that the data from agents with similar mechanisms of action--mifepristone and asinopril--are also very supportive.
In short, I have no idea why the share price is so low unless it is related to trading considerations on the part of larger investors. Which is fine, I guess, because I plan to double my position over the next few months.
AI
Market Data 
Markets 
